Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

WATERTOWN, Mass. - Tectonic Therapeutic, Inc. (NASDAQ: TECX), a biotechnology company specializing in the development of therapeutic proteins and antibodies, announced today that it has entered into a ...

Timothy A. Springer, a director and ten percent owner of Tectonic Therapeutic, Inc. (NASDAQ:TECX), has significantly increased his stake in the company through recent stock purchases. According to a ...

Tectonic Therapeutic (TECX) announced that it has entered into a securities purchase agreement for a private investment in public equity ...

Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Tectonic will issue an aggregate of 3,689,465 shares of common stock at a price of $50.00 per share to fund ...

Tectonic recently announced its third-quarter 2024 financial results, highlighting signif Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension i ...

A single dose of the investigational therapy TX45 improved heart function and blood flow, or hemodynamics, in people with pulmonary hypertension and heart failure with preserved ejection fraction ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) has announced a significant $185 million private placement financing. The private ...

What especially shook investors was the prospect that China may have closed the tech gap with the United States in AI and especially DeepSeek’s claim that it developed R1 for just $5.6 million—a far ...